Six Month Outcomes from VENOS-2 Early Feasibility Study of the Velocity® pAVF System Reported during 2026 Society of Interventional Radiology (SIR) Meeting

Apr 18, 2026

We are excited to announce that the abstract, The VENOS-2 Early Feasibility Study: Six-Month Outcomes of the Velocity® Percutaneous Arteriovenous Fistula System (NCT06712251) was presented by Bart Dolmatch, MD as a  featured late breaking abstract at the recent SIR...

One Year Outcomes from VENOS-1 First-in-Human Study of the Velocity® pAVF System Published in the Journal of Endovascular Therapy

Dec 1, 2025

Los Gatos, California – December 1, 2025 – Venova Medical, a privately held company developing a next generation technology for the creation of percutaneous arteriovenous fistulas (pAVF) for hemodialysis access, announced today the publication of first-in-human...

Venova Medical Announces First Subjects Enrolled in VENOS-3 Pivotal IDE Study of the Velocity® Percutaneous AVF System

Nov 6, 2025

Los Gatos, California – November 6, 2025 – Venova Medical, a privately held company developing a next generation technology for the creation of percutaneous arteriovenous fistulas (pAVF) for hemodialysis access, announced today the enrollment of the first subjects in...

Mid-Term Outcomes from VENOS-2 Early Feasibility Study of the Velocity® pAVF System Reported during 2025 Controversies in Dialysis Access (CiDA) Meeting

Nov 3, 2025

Rishi Razdan, MD, Medical Director of Azura Vascular Care Jacksonville in Jacksonville, Florida, presented mid-term results from the Venova Medical sponsored VENOS-2 study during the 2025 Controversies in Dialysis Access (CiDA) meeting held in Boston, Massachusetts....

Venova Medical Receives FDA IDE Approval for the VENOS-3 Pivotal Study of the Velocity® Percutaneous AVF System

Aug 21, 2025

Los Gatos, California – August 21, 2025 – Venova Medical, a privately held company developing a next generation technology for the creation of percutaneous arteriovenous fistulas (pAVF) for hemodialysis access, today announced approval from the US Food and Drug...

Venova Medical Announces Completion of Enrollment for VENOS-2 IDE Study of the VelocityTM Percutaneous AVF System

Apr 17, 2025

Los Gatos, California – Venova Medical, a privately held company developing a next generation technology for the creation of percutaneous arteriovenous fistulas (pAVF) for hemodialysis access, today announced the successful completion of patient enrollment for the...

Venova Medical Announces First Subjects Enrolled in VENOS-2 IDE Study of the Velocity Percutaneous AVF System

Jan 15, 2025

Los Gatos, California – Venova Medical, a privately held company developing a next generation technology for the creation of percutaneous arteriovenous fistulas (pAVF) for hemodialysis access, announced today the enrollment of the first participants in the company’s...

Venova Medical to Present Results from VENOS-1 Study at American Society of Nephrology (ASN) Kidney Week 2024

Oct 15, 2024

(Los Gatos, California) – Venova Medical, Inc. (Venova Medical), a privately held company developing a next generation technology for the creation of percutaneous arteriovenous fistulas (pAVF) for hemodialysis access today announced that it will present an oral...

Renal Interventions Reports on Dr. Robert Shahverdyan’s Presentation of Results from VENOS-1 Study during the 2024 Controversies in Dialysis Access (CiDA) meeting

Oct 15, 2024

Robert Shahverdyan, MD, from Hamburg, Germany presented one-year results from the VENOS-1 first-in-human study, which examined the VelocityTM Percutaneous Arteriovenous Fistula (pAVF) System during the recent Controversies in Dialysis Access (CiDA) meeting held in...

Venova Medical Announces $30 Million Series B Financing and Appointment of New Board Member

Sep 4, 2024

Funding Will Support Clinical Studies of the VelocityTM pAVF System in Patients with Chronic Kidney and End-Stage Renal Disease  (Los Gatos, California) – Venova Medical, Inc. (Venova Medical), a privately held company developing a next generation technology for...